octreotide LAR
Selected indexed studies
- [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. (Lancet, 2024) [PMID:38851203]
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. (J Clin Oncol, 2009) [PMID:19704057]
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. (Neuroendocrinology, 2017) [PMID:26731483]
_Worker-drafted node — pending editorial review._
Connections
octreotide LAR is a side effect of
Sources
- Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. (2017) pubmed
- [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. (2024) pubmed
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. (2009) pubmed
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. (2017) pubmed
- Octreotide LAR: safety and tolerability issues. (2009) pubmed
- Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. (2003) pubmed
- Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. (2010) pubmed
- Octreotide LAR for the treatment of acromegaly. (2008) pubmed
- From somatostatin to octreotide LAR: evolution of a somatostatin analogue. (2009) pubmed
- Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. (1997) pubmed